Endocrine Responses to Triptorelin in Healthy Women, Women With Polycystic Ovary Syndrome, and Women With Hypothalamic Amenorrhea
© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society..
CONTEXT: Limited data exist regarding whether the endocrine response to the gonadotropin-releasing hormone receptor agonist (GnRHa) triptorelin differs in women with polycystic ovary syndrome (PCOS) compared with healthy women or those with hypothalamic amenorrhea (HA).
OBJECTIVE: We compared the gonadotropin response to triptorelin in healthy women, women with PCOS, or those with HA without ovarian stimulation, and in women with or without polycystic ovaries undergoing oocyte donation cycles after ovarian stimulation.
METHODS: The change in serum gonadotropin levels was determined in (1) a prospective single-blinded placebo-controlled study to determine the endocrine profile of triptorelin (0.2 mg) or saline-placebo in healthy women, women with PCOS, and those with HA, without ovarian stimulation; and (2) a retrospective analysis from a dose-finding randomized controlled trial of triptorelin (0.2-0.4 mg) in oocyte donation cycles after ovarian stimulation.
RESULTS: In Study 1, triptorelin induced an increase in serum luteinizing hormone (LH) of similar amplitude in all women (mean peak LH: healthy, 52.3; PCOS, 46.2; HA, 41.3 IU/L). The AUC of change in serum follicle-stimulating hormone (FSH) was attenuated in women with PCOS compared with healthy women and women with HA (median AUC of change in serum FSH: PCOS, 127.2; healthy, 253.8; HA, 326.7 IU.h/L; P = 0.0005). In Study 2, FSH levels 4 hours after triptorelin were reduced in women with at least one polycystic morphology ovary (n = 60) vs normal morphology ovaries (n = 91) (34.0 vs 42.3 IU/L; P = 0.0003). Serum anti-Müllerian hormone (AMH) was negatively associated with the increase in FSH after triptorelin, both with and without ovarian stimulation.
CONCLUSION: FSH response to triptorelin was attenuated in women with polycystic ovaries, both with and without ovarian stimulation, and was negatively related to AMH levels.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:108 |
|---|---|
| Enthalten in: |
The Journal of clinical endocrinology and metabolism - 108(2023), 7 vom: 16. Juni, Seite 1666-1675 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Abbara, Ali [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 19.06.2023 Date Revised 02.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1210/clinem/dgad026 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351641181 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351641181 | ||
| 003 | DE-627 | ||
| 005 | 20240202231922.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1210/clinem/dgad026 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1278.xml |
| 035 | |a (DE-627)NLM351641181 | ||
| 035 | |a (NLM)36653328 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Abbara, Ali |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Endocrine Responses to Triptorelin in Healthy Women, Women With Polycystic Ovary Syndrome, and Women With Hypothalamic Amenorrhea |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.06.2023 | ||
| 500 | |a Date Revised 02.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. | ||
| 520 | |a CONTEXT: Limited data exist regarding whether the endocrine response to the gonadotropin-releasing hormone receptor agonist (GnRHa) triptorelin differs in women with polycystic ovary syndrome (PCOS) compared with healthy women or those with hypothalamic amenorrhea (HA) | ||
| 520 | |a OBJECTIVE: We compared the gonadotropin response to triptorelin in healthy women, women with PCOS, or those with HA without ovarian stimulation, and in women with or without polycystic ovaries undergoing oocyte donation cycles after ovarian stimulation | ||
| 520 | |a METHODS: The change in serum gonadotropin levels was determined in (1) a prospective single-blinded placebo-controlled study to determine the endocrine profile of triptorelin (0.2 mg) or saline-placebo in healthy women, women with PCOS, and those with HA, without ovarian stimulation; and (2) a retrospective analysis from a dose-finding randomized controlled trial of triptorelin (0.2-0.4 mg) in oocyte donation cycles after ovarian stimulation | ||
| 520 | |a RESULTS: In Study 1, triptorelin induced an increase in serum luteinizing hormone (LH) of similar amplitude in all women (mean peak LH: healthy, 52.3; PCOS, 46.2; HA, 41.3 IU/L). The AUC of change in serum follicle-stimulating hormone (FSH) was attenuated in women with PCOS compared with healthy women and women with HA (median AUC of change in serum FSH: PCOS, 127.2; healthy, 253.8; HA, 326.7 IU.h/L; P = 0.0005). In Study 2, FSH levels 4 hours after triptorelin were reduced in women with at least one polycystic morphology ovary (n = 60) vs normal morphology ovaries (n = 91) (34.0 vs 42.3 IU/L; P = 0.0003). Serum anti-Müllerian hormone (AMH) was negatively associated with the increase in FSH after triptorelin, both with and without ovarian stimulation | ||
| 520 | |a CONCLUSION: FSH response to triptorelin was attenuated in women with polycystic ovaries, both with and without ovarian stimulation, and was negatively related to AMH levels | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a GnRH agonist | |
| 650 | 4 | |a hypothalamic amenorrhea (HA) | |
| 650 | 4 | |a polycystic ovary syndrome (PCOS) | |
| 650 | 4 | |a triptorelin | |
| 650 | 7 | |a Triptorelin Pamoate |2 NLM | |
| 650 | 7 | |a 08AN7WA2G0 |2 NLM | |
| 650 | 7 | |a Luteinizing Hormone |2 NLM | |
| 650 | 7 | |a 9002-67-9 |2 NLM | |
| 650 | 7 | |a Follicle Stimulating Hormone |2 NLM | |
| 650 | 7 | |a 9002-68-0 |2 NLM | |
| 650 | 7 | |a Anti-Mullerian Hormone |2 NLM | |
| 650 | 7 | |a 80497-65-0 |2 NLM | |
| 700 | 1 | |a Phylactou, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Eng, Pei Chia |e verfasserin |4 aut | |
| 700 | 1 | |a Clarke, Sophie A |e verfasserin |4 aut | |
| 700 | 1 | |a Pham, Toan D |e verfasserin |4 aut | |
| 700 | 1 | |a Ho, Tuong M |e verfasserin |4 aut | |
| 700 | 1 | |a Ng, Kah Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Mills, Edouard G |e verfasserin |4 aut | |
| 700 | 1 | |a Purugganan, Kate |e verfasserin |4 aut | |
| 700 | 1 | |a Hunjan, Tia |e verfasserin |4 aut | |
| 700 | 1 | |a Salim, Rehan |e verfasserin |4 aut | |
| 700 | 1 | |a Comninos, Alexander N |e verfasserin |4 aut | |
| 700 | 1 | |a Vuong, Lan N |e verfasserin |4 aut | |
| 700 | 1 | |a Dhillo, Waljit S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of clinical endocrinology and metabolism |d 1945 |g 108(2023), 7 vom: 16. Juni, Seite 1666-1675 |w (DE-627)NLM00001821X |x 1945-7197 |7 nnns |
| 773 | 1 | 8 | |g volume:108 |g year:2023 |g number:7 |g day:16 |g month:06 |g pages:1666-1675 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1210/clinem/dgad026 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 108 |j 2023 |e 7 |b 16 |c 06 |h 1666-1675 | ||